Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Department of Anatomy and Neurobiology, Virginia Commonwealth University Medical Center Richmond, VA, USA.
Neuronal plasticity is an essential property of the brain that is impaired in different neurological conditions. Phosphodiesterase type 1 (PDE1) inhibitors can enhance levels of the second messengers cAMP/cGMP leading to the expression of neuronal plasticity-related genes, neurotrophic factors, and neuroprotective molecules. These neuronal plasticity enhancement properties make PDE1 inhibitors good candidates as therapeutic agents in many neurological conditions. However, the lack of specificity of the drugs currently available poses a challenge to the systematic evaluation of the beneficial effect of these agents. The development of more specific drugs may pave the way for the use of PDE1 inhibitors as therapeutic agents in cases of neurodevelopmental conditions such as fetal alcohol spectrum disorders and in degenerative disorders such as Alzheimer's and Parkinson's.
Images from this publication.See all images (2) Free text
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on